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Abstract
Maintenance therapy is emerging as a treatment strategy in the management of advanced non small cell lung
cancer (NSCLC). Initial trials addressing the question of duration of combination chemotherapy failed to show any
overall survival benefit for the prolonged administration over a fixed number of cycles with an increased risk for
cumulative toxicity. Nowadays several agents with different ways of administration and a different pattern of
toxicity have been formally investigated in the maintenance setting. Maintenance strategies include continuing
with an agent already present in the induction regimen or switching to a different one. Taking into consideration
that no comparative trials of maintenance with different chemotherapy drugs or targeted agents have been
conducted, the choice and the duration of maintenance agents is largely empirical. Furthermore, it is still unknown
and it remains an open question if this approach needs to be proposed to every patient in the case of partial/
complete response or stable disease after the induction therapy. Here, we critically review available data on
maintenance treatment, discussing the possibility to tailor the right treatment to the right patient, in an attempt to
optimize costs and benefits of an ever-growing panel of different treatment options.
Introduction
Lung cancer is the leading cause of cancer mortality in
U S Aa n dw o r l d w i d em o r et h a no n em i l l i o np e o p l ed i e
from this disease every year: the overall 5-year relative
survival rate measured by the Surveillance Epidemiology
and End Results program in USA is 15.8% [1]. Approxi-
mately 87% of lung cancer cases are Non Small Cell
Lung Cancer (NSCLC) and the majority of patients pre-
sents with advanced stage disease at diagnosis [2,3]. In
two independent phase III trials the addition of bevaci-
zumab to standard first-line therapy was shown to
improve both overall response rate (ORR) and PFS,
although OS advantage was demonstrated in only one of
these studies [4,5]. In combination with platinum-based
chemotherapy, cetuximab has also demonstrated a small
statistically significant OS advantage as compared to
chemotherapy alone [6]. Second-line treatment has been
shown to improve survival and to palliate symptoms:
approved treatment options include cytotoxic che-
motherapy (docetaxel or pemetrexed) or epidermal
growth factor - EGFR tyrosine kinase inhibitors (erloti-
nib or gefitinib) [7,8]. However, only approximately 50%
of the patients will be able to receive second-line ther-
apy, mainly because of the worsening of clinical condi-
tions [9].
One of the strategies, that has been extensively investi-
gated in recent years in order to improve current clini-
cal results in advanced NSCLC, is the maintenance
therapy. Here, we review available data on maintenance
treatment, discussing about the possibility to tailor the
right treatment to the right patient, in an attempt to
optimize costs and benefits of an ever-growing panel of
different treatment options.
Maintenance therapy: working definitions
The U.S. National Cancer Institute’s medical dictionary
defines maintenance therapy as “any treatment that is
given to keep cancer from progressing after it has been
successfully controlled by the appropriate front-line
therapy; it may include treatment with drugs, vaccines
or antibodies, and it should be given for a long time”.
Maintenance therapy has also been referred to as “con-
solidation therapy” or “early second-line therapy”,
depending on treatment type and timing of the specific
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any medium, provided the original work is properly cited.therapeutic agent employed [10]. The latter definition is
probably the least appropriate, because “second-line”
implies a disease progression event, which, by definition,
is not the case for the maintenance setting and the term
“switch maintenance” (used in the National Comprehen-
sive Cancer Network - NCCN - Clinical Practice Guide-
lines) appears more precise[11].
Currently, for advanced NSCLC the options to con-
tinue treatment after first-line induction include: 1) con-
tinuing induction therapy for a fixed number of
additional cycles over the standard or, when possible,
until progression; 2) continuing only the third-genera-
tion non-platinum compound used in the induction
regimen; 3) switching to a different agent after induction
therapy.
Continuing first-line induction therapy
The first American Cancer Society of Clinical Oncology
(ASCO) guidelines, published in 1997, addressed the
appropriate duration of therapy in advanced NSCLC
recommending no more than eight cycles, even if in
most clinical trials the median number of delivered
cycles is typically three or four [12]. Four trials clarified
that were no response, survival or QoL differences
between short versus longer treatments in advanced
NSCLC but an increased risk for cumulative toxicity
only (Table 1) [13-16]. As consequence ASCO changed
recommendations regarding the appropriate duration of
therapy in 2003, stating that treatment should have been
stopped at four cycles for non responders patients and
no more than six cycles should have been administered
for any patient; no major changes for this specific issue
were reported in the ASCO guideline update in 2009
[17,18].
Continuing the same non-platinum compound
used in the induction regimen
In patients responding or stable after the induction, a
maintenance strategy should be to continue the same
therapy withholding platinum, in an attempt at
consolidating disease control and increasing survival,
maintaining tolerability within acceptable limits.
The European Cooperative Oncology Group con-
ducted a phase III trial testing gemcitabine maintenance
versus best supportive care (BSC) in 350 patients with
complete/partial response or stable disease after four
cycles of gemcitabine/cisplatin induction, randomized in
a 2:1 ratio. Sixty one percent of patients (among 73% of
responders after the induction) were randomized: during
the maintenance period, patients received a median of
three cycles of gemcitabine (range: 0-38 cycles). Median
TTP was significantly longer in the gemcitabine arm
both throughout the study (6.6 versus 5 months, p <
0.001) and during the maintenance period (3.6 versus 2
months, p < 0.001). Median OS in the gemcitabine arm
was 13 months, compared to 11 months in the BSC arm
(p = 0.195). In terms of toxicity, the most important dif-
ference between the two arms during the maintenance
phase was the need for red blood cells transfusions (20%
in the gemcitabine arm versus 6.3% in the BSC arm, p =
0.018) [19]. Another phase III trial comparing gemcita-
bine versus BSC as maintenance therapy for patients not
progressing after 4 cycles of gemcitabine/carboplatin
induction was recently presented. Two hundred and
fifty five patients (among 519 enrolled) were rando-
mized; median PFS was 3.9 months (95% CI: 3.3-5.6) for
the experimental arm and 3.8 months (95% CI: 2.6-5.5)
for the BSC arm; median OS (primary end point) was 8
months (95% CI: 6.0-10.2) for the gemcitabine mainte-
nance arm and 9.3 months (95% CI: 7.7-12.7) for the
BSC arm, without any statistical difference [20]. In a
third trial employing gemcitabine or erlotinib mainte-
nance after 4 cycles of gemcitabine/cisplatin induction
and with a preplanned II-line treatment option (peme-
trexed), PFS (primary end point) by independent review
was significantly prolonged by both G (HR 0.51, 95% CI
0.39-0.66) and E (HR 0.83, 95% CI 0.73-0.94), as com-
pared to O. OS data are not yet mature [21]. Belani et
al. treated 401 patients with carboplatin and paclitaxel
for 16 weeks; responding patients were then randomly
assigned to receive weekly paclitaxel maintenance or
Table 1 Randomized or prolonged therapy in older chemotherapy regimens
Trial N Treatment arm Completed treatment* PFS p OS P References
Smith 2001 308 3 vs 6 mytomicin/cisplatin/vinblastine 72% vs 31% 5 mo vs 5 0.4 6 mo vs 7 0.2 [13]
Socinski 2002 230 4 Carboplatin/Paclitaxel vs Carboplatin/
Paclitaxel until PD
57% vs 42%receiving
>4cycles#
- - 6.6 mo vs
8.5
0.63 [14]
Von Plessen
2006
297 3 vs 6 Carboplatin/Vinorelbine 78% vs 54% 16 wks vs
21
0.21 28 w vs 32 0.75 [15]
Park 2007 314 4 vs 6 cycles platinum-based therapy 68% vs 92% 4.6 mo vs
6.2
0.001 14.9 mo vs
15.9
0.41 [16]
PFS: progression free survival, OS: overall survival; PD: progressive disease; mo: months; wks: weeks;
*Percentage of patients who received the all planned courses of therapy
#the percentage of grade 2-4 neuropathy in four arm cycles was 19% versus 43% in eight arm cycles.
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who were deemed eligible for randomization into the
maintenance phase, during which only 23% completed
four cycles. Median TTP (primary endpoint) was 38
weeks in the paclitaxel arm versus 29 weeks in the BSC
arm (p not reported); median OS was 75 and 60 weeks
in the paclitaxel and BSC arm, with 1-year survival rates
of 72% and 60%, respectively. During maintenance ther-
apy, 86% of patients in the chemotherapy arm experi-
enced at least one adverse event and 45% reported at
least one grade 3 or 4 adverse event [22].
Switching to a different agent after a platinum-
based induction
According to the Goldie-Coldman hypothesis, showing
that even the smallest detectable cancers contain at least
one drug resistant clone and that increasing numbers of
resistant clones emerge as tumors grow and progress, a
rational strategy would be to use all effective drugs as
early as possible in the treatment program [23,24]. Dif-
ferent non-cross-resistant agents have been used as a
maintenance strategy after a defined number of induc-
tion cycles with a platinum-based regimen in several
randomized clinical trials (Table 2).
Vinorelbine versus placebo
Westeel et al. designed a trial testing vinorelbine main-
tenance in stage IIIB and IV NSCLC after induction
with mitomycin, ifosfamide and cisplatin (MIC). Nearly
600 patients were recruited and 181 were randomized to
receive vinorelbine maintenance or BSC for up to 6
months. Mean duration of therapy was 13.8 months and
23% of patients completed 6 months of vinorelbine: in
the majority of cases treatment interruption was due to
disease progression (38%) or treatment toxicity (21%).
The HR for OS, after adjusting for stage, was 1.08 (95%
CI = 0.79 to 1.47; p = .65) and median OS was 12.3
months in both arms. One- and 2-year survival rates
were 42.2% and 20.1% in the vinorelbine arm and 50.6%
and 20.2% in the BSC arm respectively (log-rank P =
.48). No difference in PFS was observed (HR = 0.77,
95% CI = 0.56 to 1.07; p = .11; median PFS 5 months
with vinorelbine and 3 months in the BSC arm) [25].
Immediate versus delayed docetaxel
Fidias and coll. conducted a phase III trial randomly
assigning patients with objective response or stable dis-
ease after four cycles of gemcitabine/carboplatin first-
line chemotherapy to immediate (’maintenance’)d o c e -
taxel or a “delayed” second-line docetaxel, initiated at
the time of disease progression. A total of 566 patients
were enrolled and 309 patients with non-progressive dis-
ease were randomized. Among 153 patients assigned to
immediate docetaxel, 145 (94.8%) received at least one
treatment cycle and among 154 patients assigned to the
to “delayed docetaxel”, 98 (62.8%) patients initiated ther-
apy. Reasons for not initiating the planned second-line
included toxicity from previous treatment, decline in PS,
and investigator’s decision. The median number of doc-
etaxel cycles administered in both arms was 4.4. There
was a statistically significant advantage in PFS (5.7 ver-
sus 2.7 months, p = .0001) with maintenance docetaxel
but, despite a 3-months improvement in median OS
(primary endpoint), the difference did not reach statisti-
cal significance (12.3 vs. 9.7 months, p = .0853)[26].
Pemetrexed versus placebo
Patients with advanced NSCLC with a disease control
after four cycles of platinum-based therapy (not includ-
ing pemetrexed) were randomized (2:1) to pemetrexed
maintenance or placebo, until disease progression. A
total of 663 patients were randomized and, among
patients randomized to pemetrexed, 48% received more
than 6 cycles of chemotherapy and 23% received more
than 10 cycles. In the intent-to treat patient population,
pemetrexed significantly improved both PFS (primary
end point; HR = 0.50, 95% CI: 0.42 to 0.61, p < 0.0001;
median PFS 4.3 and 2.6 months, respectively) and OS
(secondary end point; HR: 0.79, 95% CI: 0.65 to 0.5, p =
0.012; median OS 13.4 and 10.6 months, respectively) as
Table 2 Studies with switch to a different agent after a platinum-based induction
First Author (N of randomized pts to
maintenance)
Maintenance Schema Primary End
Point
Median PFS
(mo)
P
value
Median OS
(months)
P
value
References
Fidias P. (309) Immediate vs delayed
docetaxel
OS 5.7 vs 2.7 0.0001 12.3 vs 9.7 0.08 [26]
Ciuleanu T. (663) Pemetrexed vs placebo PFS 4.3 vs 2.6 0.0001 13.4 vs 10.6 0.012 [27]
Cappuzzo F. (889) Erlotinib vs placebo PFS 12.3 vs 11.1 0.0001 12 vs 11 0.063 [31]
Perol M. (464) Gemcitabine vs erlotinib
vs placebo
PFS 3.7 vs 2.8 vs
2.1
nr HR 0.86 vs 0.81 na [21]
Kabbinavar F.* (768) Bevacizumab ± Erlotinib PFS 4.8 vs 3.7 0.006 Na na [32]
Gaafar RM (173) Gefitinib vs placebo OS 4.1 vs 2.9 0.0015 Na na [33]
*In this trial bevacizumab was already present in the induction therapy
nr: not reported, na: not available
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histology was incorporated into the protocol showing
consistent data with other recent studies using peme-
trexed [28,29]. In the non-squamous subgroup, peme-
trexed strikingly improved PFS (HR = 0.44, 95% CI:0.36
to 0.55 median PFS 4.5 and 2.6 months, respectively)
and OS (HR 0.70 95% CI: 0.56 to 0.88; p = 0.02, interac-
tion p value 0.033) with a median survival advantage of
5 months (15.5 months versus 10.3 months). A signifi-
cant delay in symptom worsening was observed on the
pemetrexed arm especially for pain and hemoptysis.
Erlotinib versus placebo
Cappuzzo et al. evaluated the benefit of the EGFR tyrosine
kinase inhibitor erlotinib as maintenance therapy in a
phase III trial comparing erlotinib versus placebo, in
patients who had not experienced disease progression
after four cycles of platinum-based therapy. The primary
endpoints were PFS in the overall population and PFS in
patients whose tumors had EGFR protein overexpression
(as determined by immunoistochemistry - IHC). Patients
assigned to erlotinib experienced a statistically significant
improvement in PFS in both the intent-to treat (HR = 0.71
95% CI: 0.62 to 0.82 p < 0.0001; median 12.3 versus 11.1
weeks, respectively) and the EGFR IHC positive patient
populations (HR = 0.69, 95% CI: 0.58 to 0.82; p < 0.0001).
In the ITT population, patients assigned to the erlotinib
arm experienced a statistically significant improvement in
OS (HR = 0.81, 95% CI:0,70 to 0,95; p = 0.0088; median
OS 12.0 versus 11.0 months, respectively). OS benefit was
consistent across all patient subgroups; however, OS data
for the EGFR mutation-positive population are highly cen-
sored and there was extensive crossover of EGFR-mutated
patients assigned to placebo to EGFR TKIs in second-line
therapy (16 of 24 patients, 67%). Patients who had stable
disease after first-line chemotherapy seemed to have a
more pronounced OS benefit with maintenance erlotinib
(median 11.9 versus 9.6 months, respectively; HR 0.72,
0.59-0.89; p = 0.0019) than those who had complete or
partial response to induction treatment (median 12.5 ver-
sus 12.0 months, respectively; HR 0.94,0.74-1.20; p =
0.618)[30,31].
Gemcitabine or erlotinib versus placebo
Perol et al. recently presented the results of a phase III
trial comparing maintenance gemcitabine or erlotinib
versus placebo in patients, whose tumors had not pro-
gressed following platinum-based chemotherapy. Among
834 patients who received induction chemotherapy, 464
were randomized to observation (O, N = 152), erlotinib
(E, N = 153) or gemcitabine (G, N = 149). A predefined
second-line therapy (pemetrexed) was built-in in the
s t u d yd e s i g ni na l la r m s .P F S( p r i m a r ye n dp o i n t )b y
independent review was significantly prolonged by both
G (HR 0.51, 95% CI 0.39-0.66) and E (HR 0.83, 95% CI
0.73-0.94), as compared to O. OS data are not yet
mature [21].
Bevacizumab/erlotinib versus bevacizumab
The ATLAS study is a phase III study designed to build
on the use of bevacizumab as maintenance therapy for
patients treated with an induction containing the same
monoclonal antibody together with a platinum-based
treatment. Specifically, the ATLAS study sought to
determine whether the addition of erlotinib to bevacizu-
mab could be more effective than bevacizumab alone,
when used in the maintenance setting. A total of 1,160
patients were enrolled and, after completion of four
induction cycles, non-progressing patients (N = 768,
66%) were randomized to receive bevacizumab alone or
in combination with erlotinib. This trial was stopped
after a planned interim efficacy analysis, reaching an
improvement in PFS, that was the primary end point.
Patients receiving erlotinib and bevacizumab experi-
enced a superior PFS compared to bevacizumab alone
(HR = 0,71, 95% CI: 0.58 to 0.86, p = 0.006; median
PFS 4.8 and 3.7 months, respectively). Post-study ther-
apy was at discretion of the investigator, and the rates
of subsequent therapies on the erlotinib/bevacizumab
and bevacizumab arms were 50.3% and 55.5%, respec-
tively. In both arms 39.7% of patients received erlotinib
as subsequent therapy. At the time of primary analysis
of PFS 31% of patients had events and no further ana-
lyses of OS are planned, due to loss of patients to fol-
low up [32].
Gefitinib versus placebo
The European Organization for the Research and Treat-
ment of Cancer 08021 evaluated the role of Gefitinib
(G) administered after standard first-line chemotherapy
in patients with advanced NSCLC. Initially all stable and
responding patients were eligible for the study, which
was then amended to require also evidence of EGFR
protein expression by IHC. This resulted in recruitment
slowing down, which ultimately led to premature study
closure, after inclusion of 173 patients. The results
showed a statistically significant difference in PFS (pri-
m a r ye n dp o i n t ;4 . 1a n d2 . 9m o n t h s ,H R=0 . 6 1 ,[ 9 5 %
CI 0.45,0.83], p = 0.0015) favouring G. The continuous
administration of G following platinum-based che-
motherapy in patients with advanced NSCLC was well
tolerated. Based on 149 of the required 514 deaths, no
difference in OS could be detected [33].
’Tailoring’ maintenance therapy: which agent to
which patient and future perspectives
As highlighted in the previous paragraphs, evidence on
the continued (maintenance) use of the same third-
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remains inconclusive with respect to gemcitabine and
frankly negative in terms of cost/benefit ratio with
respect to weekly paclitaxel [20-22,34]. Nowadays, avail-
able data about pemetrexed in maintenance setting do
not answer to the question if this approach could be
useful in those patients responding to a first line with
platinum compound and pemetrexed and the answer
will be available soon from a randomized trial compar-
ing pemetrexed versus placebo in patients who do not
progress following four cycles of pemetrexed plus cispla-
tin [35]. Positive data in terms of cost-effectiveness
switching to pemetrexed, which employment in non-
squamous NSCLC is really cost-effective, are driven by
its impact on PFS and OS [36]. This is indeed a crucial
point: resources use and costs involved with this new
paradigm in the clinic, would all argue for a meaningful
improvement in survival as a critical necessity from a
practical standpoint. As a consequence, the usefulness
of maintenance therapy has to be based on a clearly
defined, reproducible and measurable endpoint. Using
PFS as the basis for the adoption of a new therapeutic
approach, may be considered as a limitation due to the
variability in the definition of progression and frequency
of response assessment across studies; in this context, it
seems very relevant to standardize PFS measurement in
definitive phase III trials. For example, in the Fidias
trial, patients on the immediate docetaxel arm under-
went radiologic assessment after cycles two, four and
six, while patients in the delayed docetaxel arm the eva-
luation was performed every three months. Timing and
the type of imaging studies used in the control arm has
been considered one of the main limitations of this
study, as unfavorably delaying detection of possible dis-
ease progression [37]. As it happens in routine daily
practice, only about two thirds of patients on the con-
trol arm was able to receive second-line docetaxel, as
opposed to 95% of patients who received the study drug
in the immediate, maintenance arm; thus, the true bene-
fit with “immediate” docetaxel in this study could be
entirely attributed to the higher proportion of patients
receiving active therapy in the maintenance setting.
Indeed, a post-hoc analysis documented an identical OS
duration of 12.5 months for patients who received doce-
taxel on either arm of the study, clearly indicating that
when patients stop first-line chemotherapy, they should
be followed closely to detect progression early and at a
time when they remain fit for further treatment [24].
The benefit of maintenance therapy can be con-
founded by the absence of a predefined post-study treat-
ment. Indeed, in JMEN trial (as well as in other ones)
the discretion given to investigators in the choice of sec-
ond-line therapy has been addressed as a major limita-
tion, because it fails to provide any insight into the
possibility that the benefit of maintenance therapy may
be obtained also by the appropriate use of the same
agent as salvage therapy at the time of disease progres-
sion. In that respect, the design of the Fidias’ trial, with
all patients receiving docetaxel as either maintenance or
second-line treatment, appears to be a methodologically
more correct study design to test the efficacy of a strat-
egy introducing a non cross-resistant agent before pro-
g r e s s i o n .I nt h eS A T U R Nt r i a lo n l yam i n o r i t yo f
patients assigned to placebo actually received an EGFR-
TKI: with the current evidence, we do not know if the
improvement in OS observed with maintenance erloti-
nib would have been the same, or reduced, if the study
protocol had imposed cross-over after disease progres-
sion. Importantly, the adoption of a pre-specified, built-
in second-line treatment option offers the advantage of
reducing the proportion of patients who do not get
access to further treatment, as demonstrated in the
recently reported trial from Perol, in which more than
80% of patients in the observation arm received second-
line pemetrexed [21,30,31].
Even if a bevacizumab maintenance in patients receiv-
ing bevacizumab combined with chemotherapy in the
context of their first-line regimen is considered common
practice on the basis of the registration trials, both of
which maintained bevacizumab until progression after
the completion of the assigned first-line regimen, with
the notable exception of the recently-presented ovarian
cancer trial clearly supporting the use of maintenance
bevacizumab, this specific issue has never been assessed
in ad hoc designed randomized trials [4,5,38]. Currently
there are at least two trials designed to clarify its role in
maintenance: the ECOG three-arm, phase III study of
Paclitaxel/Carboplatin/Bevacizumab followed by rando-
mization to pemetrexed versus bevacizumab versus
pemetrexed/bevacizumab in non-squamous carcinoma
and a study with Pemetrexed/Cisplatin/Bevacizumab fol-
lowed by Pemetrexed/Bevacizumab versus Bevacizumab
alone [39]. The approximately 4-month median PFS
with single-agent erlotinib maintenance in the SATURN
trial and 4.76 months with the combination of erlotinib
and bevacizumab in the ATLAS trial, highlights the
importance of establishing the relative contribution of
each agent when a combination therapy strategy is
being evaluated in the maintenance setting [31,32].
Another related question is whether subgroups of
patients with specific clinico-pathological and/or mole-
cular characteristics would especially benefit from the
choice of a particular maintenance agent, among those
currently available. Within the limits imposed by such
methodological considerations, the only biomarker that
clearly showed a statistically significant, quantitative
interaction with the treatment assigned (erlotinib or pla-
cebo) was the presence of sensitizing EGFR mutations
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M- patients derive a small, but statistically significant,
benefit in PFS from erlotinib maintenance (HR: 0.78,
95% CI: 0.63-0.96, p = 0.0185), the PFS gain of EGFR M
+ patients is exceptionally wide (HR: 0.10, 95% CI: 0.04-
0.25, p < 0.0001). The potential benefits of the inclusion
of erlotinib in the maintenance treatment of EGFR M+
patients were consistent in the ATLAS trial, where erlo-
tinib was combined with bevacizumab. However, at the
moment there are no survival data and no further ana-
lyses of OS are planned, due to loss of patients to follow
up [32]. In routine clinical practice obtaining informa-
tion on EGFR mutational status is not always easy and
time-consuming, being not exceptional that such infor-
mation becomes available only when the patient is
already receiving a standard first-line chemotherapy
treatment: should this be the case, EGFR M+ patients
have now the option to receive TKI right after the
induction. The impact of erlotinib maintenance on OS
of EGFR M+ patients, however, is currently uncertain.
Survival data in EGFR M+ patients included in
SATURN trial are not yet mature although the low
number of EGFR M+ patients and the shape of the sur-
vival curves, make it unlikely that a statistically signifi-
cant benefit will become apparent with longer follow up.
It is true that EGFR TKI are effective in advanced
N S C L Ce v e nw h e na d m i n i s t e r e dl a t ei nt h ec o u r s eo f
the disease, but recent data document that about 50% of
NSCLC patients treated with EGFR-TKIs will develop
resistance-inducing EGFR mutations (such as the
T790M) implying the possibility that resistant clones
may expand as disease progresses [40-42]. Talking about
costs in this specific context a recent retrospective cost-
effectiveness analysis by Bradbury et al. reported the
cost per year of life gained being not the most favorable
in patients with sensitizing mutations in the EGFR gene.
This was because these patients derived relatively
greater benefit and stayed on treatment longer, thereby
incurring considerably higher drug acquisition costs
[43]. Besides EGFR mutations, histology represents a
potentially crucial decision factor for the choice of
specific maintenance agents. Currently, no direct com-
parisons between different agents in histology-selected
subgroups of patients have been reported. In the JMEN
trial, the benefit of maintenance pemetrexed is clearly
confined to patients with non-squamous histology:
indeed, in patients with squamous histology OS on
pemetrexed maintenance was indistinguishable from
that on placebo; conversely, in non-squamous patients
pemetrexed maintenance resu l t e di nar e d u c t i o no ft h e
risk of death of approximately 30% and prolonged med-
ian survival from 10.3 to 15.5 months [27]. In the
SATURN trial, non-squamous patients on erlotinib
maintenance experienced a 21% reduction in the risk of
death and a prolongation of median survival from 10.5
to 13.7 months [31]. Similar results were obtained in the
IFCT-GFPC trial (for which only PFS data are available),
where the benefit for erlotinib maintenance was also
confined to adenocarcinoma patients [21]. Conversely,
in the ATLAS trial the benefit in OS gained from the
addition of erlotinib to bevacizumab is very limited in
both the adenocarcinoma and non-adenocarcinoma
groups of patients (HR 0.91, 95% CI 0.74-1.12 and HR
0.98, 95% CI 0.64-1.49, respectively) [32]. Overall, in
patients with non-squamous histology pemetrexed
maintenance appears to provide the greatest benefit in
terms of both PFS (HR 0.44) and OS (HR 0.70). Erlotinib
also represents a reasonable choice (HR 0.60 and 0.79 for
PFS and OS respectively) and may possibly be preferable
in selected subgroups, such as females (HR 0.64 for erloti-
nib vs. HR 0.83 for pemetrexed) and east Asians patients
(HR 0.66 for erlotinib vs. HR 1.05 for pemetrexed). An
improvement in PFS was obtained with either erlotinib in
patients with squamous histology in the SATURN trial
(HR 0.76, 95% CI 0.60-0.95) or gemcitabine in patients
with non-adenocarcinoma histology in the IFCT-GFPC
trial (HR 0.56, 95% CI 0.37-0.85)[21,32]. Many other phase
II and III trials are currently ongoing looking at mainte-
nance therapy in NSCLC (Tables 3 and 4) [35,39,44,45].
Modulating the immune response in lung cancer is a strat-
egy that is being actively investigated also in maintenance
approach. The L-BLP25 (Stimuvax; Biomira Alberta, CA)
Table 3 New Phase II trials
Trial/Author Comparison Comments References
NCT00867009 Pemetrexed and Cisplatin Plus Cetuximab Followed by Pemetrexed and Cetuximab as
Maintenance IIIB or IV Nonquamous NSCLC
ongoing, but not
recruiting
[39]
NCT00687297 Vandetanib (ZD6474)n With Docetaxel and Carboplatin Followed by Placebo or Vandetanib as
Maintenance in IIIb, IV or Recurrent NSCLC
ongoing, but not
recruiting
[39]
NCT01004250 Pemetrexed, Cisplatin, and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab
as Maintenance, in First-Line Nonsquamous Advanced NSCLC
currently
recruiting
[39]
NCT00425646 Maintenance Strategy of Gleevce
® (Imatinib Mesylate) and Bevacizumab in Advanced, Non-
Squamous, NSCLC Following Completion of First-Line Chemotherapy With Bevacizumab
ongoing, but not
recruiting
[39]
NCT00766246 Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus
Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV NSCLC
currently
recruiting
[39]
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peptide of mucine 1 (MUC 1), a transmembrane protein
expressed on epithelial cells. In a phase IIb trial, patients
in stage III NSCLC, who had disease control after induc-
tion therapy, were randomized to receive vaccination
weekly for 8 weeks and then they had the option to pro-
ceed to maintenance therapy, consisting in vaccination
every 6 weeks or BSC. The median OS (primary endpoint)
was 17.4 months for the vaccinated patients versus 13.0
months for those on BSC arm (p = 0.66)[46].
Conclusions
Since no comparative trials of maintenance with different
chemotherapy drugs or targeted agents have been con-
ducted, no conclusive data are available yet of an advan-
tage of maintenance therapy. As consequence, the choice
and the duration of maintenance treatment remains lar-
gely empirical and needs to be explained and discussed
with each patients in terms of current trials, different
toxicity profiles (fatigue and myelosuppression on che-
motherapy versus rash and diarrhea on EGFR TKis) or
intra venous versus oral treatment options [47]. On the
basis of the previous data in patients for whom mainte-
nance therapy is deemed appropriate and who accepted
to prolong treatment: i) switching to a non cross-resis-
tant agent appears to provide greater benefit than conti-
nuing on one of the agents employed in the induction
regimen (although critical information on this issue will
be provided by the PARAMOUNT S124 trial, which
investigated pemetrexed maintenance after pemetrexed/
cisplatin induction and recently concluded enrollment)
ii) in patients harboring sensitizing EGFR mutations,
erlotinib (either alone or combined with bevacizumab for
patients who have received bevacizumab as part of their
primary treatment, if future data will state a benefit) cur-
rently appears to be the agent of choice iii) in patients
with non-squamous/adenocarcinoma histology and with
wt-EGFR or unknown mutational status, pemetrexed
appears to provide the greatest advantage, although erlo-
tinib, and to a lesser extent gefitinib (where available),
m a yb er e a s o n a b l ea l t e r n a t i v e sf o rs e l e c t e dp a t i e n t s ,t a k -
ing into account the possible patient preference for an
oral treatment option iv) patients with squamous histol-
ogy and patients with KRAS mutations have limited
treatment options and should be enrolled in specific clin-
ical trials whenever possible.
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Table 4 Current PHASE III trials
Trial/Author Comparison Comments References
NCT01107626
ECOG 5508
Paclitaxel/Carboplatin/Bevacizumab, followed by pemetrexed vs bevacizumab vs pemetrexed/
bevacizumab
not yet open for
recruitment
[39]
NCT00789373
Paz-Ares LG
Maintenance Pemetrexed/BSC Vs BSC Immediately Following Induction Treatment With
Pemetrexed + Cisplatin for Advanced Nonsquamous NSCLC
currently
recruiting
[39]
NCT00762034
Patel et al.
Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab vs
Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in IIIB or IV
Nonsquamous NSCLC
currently
recruiting
[39]
NCT00820755
NEXT
Platinum-based chemotherapy plus cetuximab followed by cetuximab as maintenance with
either 500 mg/m
2 every 2 w or 250 mg/m
2 every w
ongoing, not
recruiting
[39]
NCT00948675
Zinner et al.
Pemetrexed/carboplatin with maintenance pemetrexed vs paclitaxel/carboplatin/bevacizumab
with maintenance bevacizumab in IIIB or IV Nonsquamous NSCLC
currently
recruiting
[39]
NCT00693992
CALGB 30607
Sunitinib as maintenance therapy vs placebo in Non-Progressing Patients Following 4 Cycles
of Platinum-Based Combination in IIIB/IV NSCLC
currently
recruiting
[39]
NCT00961415
AVAPERL1
Bevacizumab with or without pemetrexed as maintenance after 4 cycles Bevacizumab/
Cisplatin/Pemetrexed
currently
recruiting
[39]
NCT00676507
STOP
Lucanix™ (Belagenpumatucel-L) as Maintenance III/IV NSCLC with SD or PR and Who Have
Responded to or Have Stable Disease Following One Regimen of Front-line, Platinum-based
Combination Chemotherapy
currently
recruiting
[39]
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